Insights

Gathering insights about Shift Pharmaceuticals…

Similar companies to Shift Pharmaceuticals

Shift Pharmaceuticals Tech Stack

Shift Pharmaceuticals uses 8 technology products and services including RSS, MySQL, oEmbed, and more. Explore Shift Pharmaceuticals's tech stack below.

RSS
Content Management System
MySQL
Database
oEmbed
Dev Tools
Google Fonts API
Font Scripts
jQuery
Javascript Libraries
Contact Form 7
Web Platform Extensions
Apache HTTP Server
Web Servers
Apache
Web Servers

Media & News

Shift Pharmaceuticals's Email Address Formats

Shift Pharmaceuticals uses at least 1 format(s):

Shift Pharmaceuticals Email Formats	Example	Percentage

Frequently Asked Questions

What is Shift Pharmaceuticals's official website and social media links?

Shift Pharmaceuticals's official website is shiftpharmaceuticals.com and has social profiles on LinkedIn.

What is Shift Pharmaceuticals's NAICS code?

Shift Pharmaceuticals's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Shift Pharmaceuticals have currently?

As of December 2025, Shift Pharmaceuticals has approximately 5 employees across 1 continents, including North America. Key team members include Chief Executive Officer: S. O.Chief Scientific Officer: C. L.Director Of Research And Development: P. M.. Explore Shift Pharmaceuticals's employee directory with LeadIQ.

What industry does Shift Pharmaceuticals belong to?

Shift Pharmaceuticals operates in the Pharmaceutical Manufacturing industry.

What technology does Shift Pharmaceuticals use?

Shift Pharmaceuticals's tech stack includes RSSMySQLoEmbedGoogle Fonts APIjQueryContact Form 7Apache HTTP ServerApache.

Shift Pharmaceuticals

Q: How many employees does Shift Pharmaceuticals have currently?

Shift Pharmaceuticals has approximately 5 employees.

Q: What technology does Shift Pharmaceuticals use?

Shift Pharmaceuticals's tech stack includes Contact Form 7, RSS, jQuery, WordPress, PHP.

Pharmaceutical ManufacturingKansas, United States2-10 Employees

Shift Pharmaceuticals is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders, including Charcot Marie Tooth Syndrome (CMT1A) and Spinal Muscular Atrophy (SMA). Rather than alleviating certain disease side effects, these molecules “SHIFT” the body’s natural protein production back into alignment effectively addressing the core cause of the disease.

We are supported with funding from the NIH, DoD, CMT Research Foundation, and Gwendolyn Strong Foundation.